Oncologica

Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK. Our personalised cancer DNA profiling is used to precisely identify the most appropriate clinical targeted therapies and/or immunotherapies which can be used to treat patients as an alternative to chemotherapy. Our molecular Next Generation Sequencing capabilities are used to sequence tumour DNA and to also sequence Covid-19/ SARS-CoV-2 for virus mutations. SARS-CoV-2 testing, and sequencing is being used to identify high risk Covid-19 variants which can potentially bypass the vaccine. Oncologica's comprehensive NGS DNA profiling covering 505 genes with linkage to over 750 targeted therapies provide patients and clinicians with detailed genomic blueprints that optimize therapy choices, improve outcomes, and helps avoid treatment with drugs unlikely to be of benefit. Oncologica also undertakes Contract Research supporting biomarker development programmes, clinical trials, and the validation of new diagnostic testing platforms. Our in-house R&D activities focus on the development of novel cancer genomic based diagnostic and therapeutic approaches directed at specific tumour gene mutations or aberrant cancer pathways.